Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$10.06 -0.08 (-0.81%)
As of 07/24/2025 03:57 PM Eastern

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Key Stats

Today's Range
$10.06
$10.10
50-Day Range
$9.23
$10.14
52-Week Range
$8.37
$13.14
Volume
59,006 shs
Average Volume
209,086 shs
Market Capitalization
$18.21 billion
P/E Ratio
59.18
Dividend Yield
3.38%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

A cyclist rides past outside the Beijing No
Chinese court sentences a Japanese man to more than 3 years in prison on espionage charges
A Japanese man has been sentenced to three and a half years in prison in China on espionage charges...
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
ALPMY Astellas Pharma Inc. - Seeking Alpha
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $9.66 at the start of the year. Since then, ALPMY shares have increased by 4.1% and is now trading at $10.06.

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its earnings results on Friday, April, 25th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.12. The company earned $3.22 billion during the quarter, compared to analysts' expectations of $3.02 billion. Astellas Pharma had a net margin of 2.65% and a trailing twelve-month return on equity of 16.55%.

Shares of Astellas Pharma split on the morning of Wednesday, April 2nd 2014.The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were payable to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

Astellas Pharma subsidiaries include Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
4/25/2025
Today
7/24/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
CIK
1446390
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

EPS (Trailing Twelve Months)
$0.17
Trailing P/E Ratio
59.18
Forward P/E Ratio
23.95
P/E Growth
N/A
Net Income
$334.93 million
Net Margins
2.65%
Pretax Margin
1.63%
Return on Equity
16.55%
Return on Assets
7.35%

Debt

Debt-to-Equity Ratio
0.37
Current Ratio
1.13
Quick Ratio
0.85

Sales & Book Value

Annual Sales
$12.56 billion
Price / Sales
N/A
Cash Flow
$1.87 per share
Price / Cash Flow
5.39
Book Value
$5.52 per share
Price / Book
1.82

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.23

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners